Diagnostics: The Good, the Bad & the Ugly

On October 26-27, I co-chaired an International Conference on “Companion Diagnostics & Biomarkers” in Porto, Portugal. The presenters included global experts in diagnostics including market leaders such as Unilabs, Agilent, Qiagen, ThermoFisher and Guardant Health. The Conference was initiated by the other Co-chair, Harry Glorikian, the author of Moneyball Medicine who delivered an engaging presentation predicting the future of medicine and digital health. Throughout the two days, impressive and informative presentations described the current status and the predicted future of diagnostics and digital health technology including the anticipated tsunami of future changes. I initiated the second day of the conference with an overview of the past, present and future of diagnostics, encompassing the best (and worst) examples of companion diagnostics (“The Good, the Bad and the Ugly”). Click here to request the presentation. Presentation by Ali Ardakani, Managing Director of Novateur Ventures: “Can Companion Diagnostics Be a Guide to Cure? The Good, the Bad and the Ugly” – BioTech Pharma Summit 2017: Companion Diagnostics & Biomarkers October 26-27, 2017 — Porto, Portugal Ali Ardakani, Managing Director of Novateur, chairing the final plenary session of the BioTech Pharma Summit 2017: Companion Diagnostics & Biomarkers October 26-27, 2017 — Porto, Portugal Here are some summarized highlights from the conference: Diagnostics will be playing an ever-encompassing role in therapeutics development and commercialization. Both EMEA and FDA are encouraging more “targeted therapeutics” with companion diagnostics. Digital Health and digital diagnostics will represent a tremendous new growth sector and will become an integral part of our health care system. Embracing this market dynamics sooner will lead to better health outcomes and reduced costs. Diagnostics...

Why Did We Go Fishing with Roche Venture Fund?

We were delighted to host Karl Handelsman, Partner at Roche Venture Fund in Vancouver last week. Over 100 participants came to his talk at BC Cancer Agency where he talked about “Winning Strategies for Biotech Startups”. Afterwards, we held a private dinner where he met several companies he had expressed interest in connecting with. The following day we went on a fishing trip with where Karl had an opportunity to connect with the biotech entrepreneurs one on one for several hours. Why did we invite Karl? We live in a geography where there is a dearth of Venture Capital funding. Most funds are located in San Francisco and Boston and unless our Canadian clients are visiting those cities on a regular basis, they would not have exposure to many VCs and family funds. We are spearheading an effort to create awareness on our innovators. If we can not all go down south, let’s bring up serious VCs to connect with our companies. Specifically, we liked Roche Venture Fund and Karl as they are interested in investing in companies that are developing early stage ground-breaking ideas. We have many of those in Canada. In addition, Karl in his previous life was involved in building a company that was sold to Amgen. We find VCs that were entrepreneurs in the past to be better investors or at least more understanding of the challenges of biotech entrepreneurship. Why did we go fishing with Karl? Investors invest in people with ideas, not just ideas. They need to meet you, feel comfortable with you and know that they can trust you. They need to...